May 26, 2021
British Society for Haematology Virtual Annual Scientific Meeting Guidelines Session 2021
Dr Eugene Oteng-Ntim presents on the draft Guidelines Management of sickle cell disease in pregnancy. The guideline is now published .
Dr Oteng-Ntim is a Consultant Obstetrician and Head of Obstetrics at Guy's and St Thomas NHS Trust Foundation. He is a Honorary Reader in Women's Health (KCL) and Honorary Associate Professor in Epidemiology and Population Health(LSHTM).
May 26, 2021
British Society Haematology Virtual Annual Scientific Meeting Guidelines Session 2021
Haemostasis and Thrombosis Presentations Question and Answer with Keith Gomez and Will Lester; hosted by Jo Howard.
May 26, 2021
British Society for Haematology Virtual Annual Scientific Meeting Guidelines Session 2021
Dr Will Lester presents on the draft Guidelines on The Assessment of bleeding risk prior to surgery or invasive procedures. The guidelines aims to be published by the end of 2021 early 2022.
Dr Lester is a Honorary Haematology Consultant at University Hospitals Birmingham NHS Foundation Trust and deputy chair of the BSH Haemostasis and Thrombosis Task Force.
May 25, 2021
British Society for Haematology Virtual Annual Scientific Meeting Guidelines Session 2021
Dr Keith Gomez presents on the final draft Guidelines for the laboratory investigation of heritable disorders of platelets function. The guideline aims to be published in the next two to three months.
Dr Gomez is an Associate Professor in Haematology and Consultant Haematologist at the Royal Free London NHS Foundation Trust and chair of the BSH Haemostasis and Thrombosis Task Force. He has extensive clinical experience in the management of bleeding disorders, such as haemophilia, and disorders of blood clotting (thrombosis).
![Good Practice Paper Preoperative patient blood management during the SARS-CoV-2 pandemic]()
May 10, 2021
Dr Alwyn Kotze presents a short podcast on the BSH Good Practice Paper Preoperative patient blood management during the SARS-CoV-2 pandemic
The focus of this good practice paper is to highlight the challenges in provision of elective surgical services while SARS-CoV-2 remains prevalent in communities.
Dr Kotze discusses the good practice paper in three sections:
1) How the good practice paper is produced and which evidence is taken in account doing so
2) How we think pandemic times have changed our pathways especially concentrating on remote working and how we believe teams can and should prioritise different aspects inherent in a patient blood management programme.
3) Clinical subject matter pandemic specific on the following:
- management of preoperative anaemia
- bleeding risk assessment and investigation
- medication management of trying to reduce bleeding
Dr Alwyn Kotze is a Consultant Anaesthetist at Leeds Teaching Hospitals NHS Trust. Dr Kotze's clinical practices is a mixture of organ transplantation specifically liver transplants and providing other anaesthesia for surgeries.
April 12, 2021
Dr Jonathan Sive presents a podcast on the BSH Guidelines on the diagnosis, investigation and initial treatment of myeloma.
The objective of this guideline is to provide healthcare professionals with clear guidance on the anti‐myeloma management of patients with newly diagnosed multiple myeloma. In all cases, individual patient circumstances may dictate an alternative approach.
Dr Sive discusses the guidelines three main focus areas:
1) Initial investigation diagnosis of myeloma
2) Choice of treatment for myeloma
3) Post treatment consolidation therapy
Dr Jonathan Sive is a Consultant Haematologist and the clinical service lead for myeloma at University College London Hospital (UCLH).
![Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V)]()
February 21, 2021
Dr Nilima Parry-Jones presents a podcast on the Guidelines for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).
Hairy cell leukaemia (HCL) is an uncommon, chronic B cell leukaemia, first reported as a distinct entity in the 1950s.1, 2 HCL accounts for 2% of lymphoid leukaemias, with a male predominance and median age at diagnosis of 58 years. Classical HCL and its variant form (HCL‐V) are now regarded as separate entities,3 with different cytological, haematological and immunophenotypic features. BRAF V600E mutation, present in virtually 100% of cases of classical HCL,4 is regarded as a disease‐defining event, and is absent in HCL‐V.
Dr Parry- Jones discusses the guideline in three parts:
Part 1: Clinical and laboratory features.
Part 2: Diagnostic tests and differential diagnosis including the use of molecular genetics.
Part 3: Therapeutics and response assessment.
Dr Nilima Parry-Jones is a Consultant Haematologist at the Aneurin Bevan Local Health, Wales.
![Guideline Frontline Management of Post Transplantation Lymphoproliferative Disorder in Adult Solid Organ Recipient Patients]()
February 21, 2021
Dr Nimish Shah presents a short podcast on the BSH Guideline Frontline Management of Post-Transplantation Lymphoproliferative Disorder in Adult Solid Organ Recipient Patients.
Dr Shah discusses the guideline in three parts:
1) PET scan and its role in PTLD
2) The management of PTLD
3) Potential new developments
This document is an updated guideline and details the recommendations for the frontline management of adult patients with an established diagnosis of post‑transplant lymphoproliferative disorder (PTLD) following solid organ transplantation (SOT).
PTLD represents a spectrum of disorders resulting from lymphoid or plasmacytic cell proliferations that occur as a result of immunosuppression following SOT. In adult SOT recipients, PTLD is the second commonest malignancy after skin cancer and is the commonest cause of cancer-related mortality1. The reported incidence varies according to patient age, transplant type and the degree of immunosuppression. Historically, PTLD has been reported to occur most frequently in the first year following transplantation. However, more recent reports suggest that PTLD occurring late (beyond the first year) may be at least as common2–5
Dr Nimish Shah is a Consultant Haematologist at the Norfolk and Norwich University Hospital NHS Foundation Trust.
![Guideline The use of prophylactic factor replacement for children and adults with Haemophilia A and B]()
February 21, 2021
Dr Rachel Rayment presents a podcast on the BSH The use of prophylactic factor replacement for children and adults with Haemophilia A and B.
Coagulation factor replacement in people with haemophilia (PWH) A or B may be given either in response to a bleed [on‐demand (OD) therapy] or regularly to prevent bleeding (prophylactic therapy). Guidelines for prophylactic treatment of children and adults with severe haemophilia A (SHA) were produced by the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) in 2010, summarising the high‐level, evidence‐based studies of prophylaxis in boys and advising on the role of prophylaxis in adults with SHA.1 This guideline builds on the former, accepting the clear evidence of benefit of prophylaxis in children with SHA. It addresses the optimum use of prophylaxis in children and adults with haemophilia A and B and gives evidence‐based recommendations where appropriate. The guidance will be of value to healthcare professionals, laboratory scientists, patients and those with a responsibility for funding services.
Dr Rachel Rayment is a Consultant Haematologist; Haemophilia and Thrombosis Centre Director as well as Clinical Lead for ITP at the Cardiff and Vale University Hospital Health Board.
![Guideline on the investigation and management of follicular lymphoma]()
February 21, 2021
Dr Kim Linton presents a podcast on the BSH Guideline on the investigation and management of follicular lymphoma.
Follicular lymphoma (FL) is a heterogeneous disease. For many it is experienced as a chronic, relapsing, indolent condition with long overall survival (OS). Most people affected have advanced disease at presentation; symptoms may include B symptoms (i.e. fever, night sweats and weight loss), fatigue and the local mass effect of lymph node enlargement. However, many people are asymptomatic at presentation. Some people are observed without treatment according to a ‘watch and wait’ policy (see section Management of patients with newly diagnosed FL). In contrast to this, over a period of many years, 20–30% of patients will die from refractory FL or following transformation of their disease to high‐grade lymphoma.1 Prognostic indices may help discriminate between risk groups (see section Prognostic factors in FL).
Dr Linton discusses the guidelines four main focus areas:
1) Important changes on the use of PET scanning.
2) Advances in the upfront management of patients with asymptomatic and symptomatic advance stage disease.
3) High risk disease in high grade transformation.
4) Advances in the management of relapse with some horizon scanning of promising drugs in development
Dr Kim Linton is Consultant Medical Oncologist at Christie NHS Foundation Trust and Clinical Senior Lecturer at the University of Manchester.
